Oculis, a clinical-stage biotechnology company focused on the development of non-invasive topical treatment for back-of-the-eye diseases, announced it has successfully closed a Series B financing round of CHF 20 million. In conjunction with the financing, Oculis is re-locating its corporate headquarters to Lausanne.
Find an actor

4à6 de BioAlps - Ferring29.05.2018

Les "4à6" de BioAlps sont une série d'événements organisés dans chacun des 7 cantons de Suisse occidentale.

Kinntek chooses Pryv

Kinntek, announces that it has chosen Pryv to extend its breakthrough hand rehabilitation interactive platform with...
Print this page Download this page (PDF) Recommend this page to a friend

Contact us

BioAlps Association
Ch. du Pré-Fleuri 3
CH - 1228 Plan-les Ouates
+41 22 304 40 40
+41 22 304 40 70

Subscribe to our newsletter

Find us on LinkedIn